MX2015012653A - Formulaciones oculares para suministro de farmaco al segmento porterior del ojo. - Google Patents

Formulaciones oculares para suministro de farmaco al segmento porterior del ojo.

Info

Publication number
MX2015012653A
MX2015012653A MX2015012653A MX2015012653A MX2015012653A MX 2015012653 A MX2015012653 A MX 2015012653A MX 2015012653 A MX2015012653 A MX 2015012653A MX 2015012653 A MX2015012653 A MX 2015012653A MX 2015012653 A MX2015012653 A MX 2015012653A
Authority
MX
Mexico
Prior art keywords
eye
posterior segment
drug
delivery
ocular formulations
Prior art date
Application number
MX2015012653A
Other languages
English (en)
Other versions
MX360888B (es
Inventor
David P Bingman
Paul G Chaney
Martin B Wax
Original Assignee
Panoptica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panoptica Inc filed Critical Panoptica Inc
Publication of MX2015012653A publication Critical patent/MX2015012653A/es
Publication of MX360888B publication Critical patent/MX360888B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere con formulaciones tópicas que comprenden un compuesto de la siguiente fórmula: (ver Fórmula) para tratar la neovascularización ocular; el Compuesto 1 está presente en una solución o una suspensión en aproximadamente 0.005% a aproximadamente 5.0% p/v, de manera que la solución o suspensión suministre el compuesto al segmento posterior del ojo para inhibir el VEGF en la retina y/o el coroide.
MX2015012653A 2013-03-14 2014-03-14 Formulaciones oculares para suministro de fármaco al segmento posterior del ojo. MX360888B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784681P 2013-03-14 2013-03-14
PCT/US2014/027589 WO2014152661A1 (en) 2013-03-14 2014-03-14 Ocular formulations for drug-delivery to the posterior segment of the eye

Publications (2)

Publication Number Publication Date
MX2015012653A true MX2015012653A (es) 2016-08-18
MX360888B MX360888B (es) 2018-11-20

Family

ID=50625096

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012653A MX360888B (es) 2013-03-14 2014-03-14 Formulaciones oculares para suministro de fármaco al segmento posterior del ojo.

Country Status (23)

Country Link
US (8) US10092549B2 (es)
EP (2) EP2968650B1 (es)
JP (3) JP6542193B2 (es)
KR (2) KR102433489B1 (es)
CN (2) CN105142686B (es)
AU (3) AU2014239252B2 (es)
BR (1) BR112015021334B1 (es)
CA (1) CA2900840C (es)
DK (1) DK2968650T3 (es)
ES (1) ES2710152T3 (es)
HK (1) HK1216236A1 (es)
HU (1) HUE042528T2 (es)
IL (2) IL240510B (es)
MX (1) MX360888B (es)
PH (2) PH12015501938A1 (es)
PL (1) PL2968650T3 (es)
PT (1) PT2968650T (es)
RU (2) RU2768489C2 (es)
SA (1) SA516380321B1 (es)
SG (2) SG10201710928PA (es)
TR (1) TR201901462T4 (es)
WO (1) WO2014152661A1 (es)
ZA (2) ZA201505447B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3181119T3 (pl) 2012-09-12 2020-01-31 Novaliq Gmbh Kompozycje semifluorowanych alkanów do zastosowania w leczeniu suchego zapalenia spojówki i rogówki
CN113679698B (zh) 2012-09-12 2022-07-26 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
ES2863601T3 (es) * 2014-09-17 2021-10-11 Panoptica Inc Formulaciones oculares para administración de fármacos y protección del segmento anterior del ojo
CN111743882A (zh) 2015-09-30 2020-10-09 诺瓦利克有限责任公司 半氟化化合物和其组合物
CA3016602A1 (en) 2016-03-11 2017-09-14 Georgia-Pacific Gypsum Llc Gypsum panels, systems, and methods
CN110678207B (zh) * 2017-04-21 2024-08-02 德马利克治疗公司 碘组合物
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
RU2652342C1 (ru) * 2017-07-13 2018-04-25 Наталья Александровна Гаврилова Композиция для лечения ретинальной неоваскуляризации в эксперименте и способ лечения с ее использованием
CN111372566A (zh) 2017-09-27 2020-07-03 诺瓦利克有限责任公司 用于治疗眼部疾病的包含拉坦前列素的眼科用组合物
WO2019068763A1 (en) 2017-10-04 2019-04-11 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING F6H8
WO2020074697A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
AT522609B1 (de) 2019-05-28 2022-06-15 Miba Frictec Gmbh Reibvorrichtung
KR20240017423A (ko) 2021-05-03 2024-02-07 아빌라 테라퓨틱스, 인크. 이뮤노글로불린 및 다른 단백질의 분해를 위한 강력한 asgpr-결합 화합물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011003A1 (en) * 1994-10-10 1996-04-18 Novartis Ag Ophthalmic and aural compositions containing diclofenac potassium
JPH10203960A (ja) 1997-01-24 1998-08-04 Ofutekusu:Kk 点眼液組成物
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
US6239113B1 (en) * 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
WO2001017527A1 (fr) * 1999-09-06 2001-03-15 Ono Pharmaceutical Co., Ltd. Agents destines a la prevention et a au traitement des maladies des yeux
SI1337521T1 (sl) * 2000-11-28 2006-12-31 Pfizer Prod Inc Soli izotiazol-4-karboksamida in njihova uporaba kot antihiperproliferacijska sredstva
MXPA05000950A (es) * 2002-07-25 2005-05-16 Pfizer Prod Inc Derivados de isotiazol utiles como agentes anticancerosos.
CN1533553A (zh) * 2002-08-29 2004-09-29 ��˹��ķ��ʽ���� 视觉辅助网络服务器,视觉辅助网络系统,视觉辅助方法,视觉辅助系统,视觉缺陷告知系统,视觉缺陷告知程序,视觉缺陷告知方法,色彩辨别辅助系统,色彩辨别辅助程序,以及色彩辨别辅助方法
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US20050234018A1 (en) 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
WO2005102327A1 (en) * 2004-04-20 2005-11-03 Pfizer Products Inc. Dosage forms and methods of treatment using vegfr inhibitors
US7483533B2 (en) * 2004-08-05 2009-01-27 King Fahd University Of Petroleum Elliptic polynomial cryptography with multi x-coordinates embedding
JP2006111621A (ja) * 2004-09-15 2006-04-27 Santen Pharmaceut Co Ltd ピレノキシン懸濁型点眼剤
AU2005304035B2 (en) * 2004-11-09 2010-07-22 Santen Sas Ophthalmic oil-in-water type emulsion with stable positive zeta potential
JP2008543775A (ja) * 2005-06-08 2008-12-04 ターゲジェン インコーポレーティッド 眼の障害を治療するための方法および組成物
JP2007011785A (ja) * 2005-06-30 2007-01-18 Toshiba Corp 情報処理装置、およびタッチパネルの振動制御方法
JP2007012937A (ja) * 2005-06-30 2007-01-18 Seiko Epson Corp 表示ドライバ
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
PL1937212T3 (pl) * 2005-10-10 2011-02-28 Santen Sas Emulsje oftalmiczne zawierające prostaglandyny
DE102006051512A1 (de) * 2005-12-06 2007-06-14 Pari GmbH Spezialisten für effektive Inhalation Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
CA2679066A1 (en) * 2007-02-22 2008-08-28 Othera Holding, Inc. Hydroxylamine compounds and methods of their use
EP2179736A4 (en) * 2007-08-09 2012-01-18 Senju Pharma Co TWO COMPONENT OPHTHALMIC DROPS CONTAINING PIRENOXIN
JP2010265261A (ja) * 2009-04-17 2010-11-25 Santen Pharmaceut Co Ltd レボカバスチン懸濁型点眼剤
JP2012250918A (ja) * 2011-05-31 2012-12-20 Rohto Pharmaceutical Co Ltd ニューキノロン剤含有水性組成物
CA2865132A1 (en) 2012-02-22 2013-08-29 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent

Also Published As

Publication number Publication date
US20160354349A1 (en) 2016-12-08
RU2768489C2 (ru) 2022-03-24
IL240510B (en) 2020-08-31
AU2019202857A1 (en) 2019-05-16
PT2968650T (pt) 2019-02-12
ZA201907176B (en) 2022-12-21
IL276016A (en) 2020-08-31
RU2665953C2 (ru) 2018-09-05
TR201901462T4 (tr) 2019-02-21
CN111789814A (zh) 2020-10-20
AU2017210543B2 (en) 2019-01-31
AU2014239252B2 (en) 2017-07-06
HUE042528T2 (hu) 2019-07-29
ES2710152T3 (es) 2019-04-23
PH12019501902A1 (en) 2021-03-01
CN105142686A (zh) 2015-12-09
EP2968650B1 (en) 2019-01-16
AU2017210543A1 (en) 2017-08-17
ZA201505447B (en) 2022-06-29
EP2968650A1 (en) 2016-01-20
JP2016517427A (ja) 2016-06-16
CA2900840C (en) 2023-03-28
KR102433489B1 (ko) 2022-08-17
US20140303219A1 (en) 2014-10-09
DK2968650T3 (en) 2019-03-11
SA516380321B1 (ar) 2019-01-16
JP6965308B2 (ja) 2021-11-10
US20190183864A1 (en) 2019-06-20
IL240510A0 (en) 2015-10-29
RU2018128980A (ru) 2018-11-05
SG11201507316UA (en) 2015-10-29
EP3520773A1 (en) 2019-08-07
RU2015143898A (ru) 2017-04-19
BR112015021334B1 (pt) 2020-04-07
US20160022646A1 (en) 2016-01-28
US10092549B2 (en) 2018-10-09
WO2014152661A1 (en) 2014-09-25
AU2014239252A1 (en) 2015-08-13
US9446026B2 (en) 2016-09-20
JP2022009275A (ja) 2022-01-14
MX360888B (es) 2018-11-20
KR20210132205A (ko) 2021-11-03
US10307404B1 (en) 2019-06-04
US20210196690A1 (en) 2021-07-01
PH12015501938B1 (en) 2016-01-11
SG10201710928PA (en) 2018-02-27
PH12015501938A1 (en) 2016-01-11
US20190240201A1 (en) 2019-08-08
IL276016B (en) 2022-04-01
HK1216236A1 (zh) 2016-10-28
RU2018128980A3 (es) 2022-01-11
CN111789814B (zh) 2022-07-19
PL2968650T3 (pl) 2019-05-31
AU2019202857B2 (en) 2021-02-18
CN105142686B (zh) 2020-04-10
US20190247368A1 (en) 2019-08-15
JP6542193B2 (ja) 2019-07-10
JP2019167377A (ja) 2019-10-03
CA2900840A1 (en) 2014-09-25
BR112015021334A2 (pt) 2017-07-18
KR20150127256A (ko) 2015-11-16
US20240325357A1 (en) 2024-10-03

Similar Documents

Publication Publication Date Title
PH12019501902A1 (en) Ocular formulations for drug-delivery to the posterior segment of the eye
MX2016014634A (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
NZ704247A (en) Compositions and treatment for eye diseases and disorders
MY171920A (en) Prevention and treatment of ocular conditions
PH12015501942A1 (en) Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders
MX2017002374A (es) Composiciones y metodos para tratar trastornos de la vision.
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
MX2016016090A (es) Composicion oftalmica para el tratamiento de infeccion ocular.
MX2017004760A (es) Formulacion esterilizada por calor que comprende quitosan y proceso para preparacion de la misma.
MX2021006070A (es) Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo.
MX2016004909A (es) Composicion que contiene eugenol como principio activo para prevenir o tratar la dermatitis atopica.
MY182591A (en) Compositions for use in treating eye disorders using dipyridamole
ZA202003944B (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
MX2019011925A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
PH12015501555A1 (en) Topical aqueous ophthalmic compositions containing a 1h-indole-1-carboxamide derivative and use thereof for treatment of ophthalmic disease
TW201613596A (en) Ophthalmic suspension preparation
HK1216233A1 (zh) 含有四氫吡喃基氨基環戊基羰基四氫吡啶並吡啶衍生物作為有效成分的眼後段疾病的預防或治療劑
GR1008505B (el) Οφθαλμικο φαρμακευτικο σκευασμα ελευθερο συντηρητικου περιεχον δορζολαμιδη και τιμολολη
GR1008509B (el) Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση περιεχον δορζολαμιδη

Legal Events

Date Code Title Description
FG Grant or registration